Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
hnps-PLA inhibitor
Cat. No.:
0225LY-0794
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Hnps-PLA Inhibitor is a specialized chemical agent designed to inhibit human nonpancreatic secretory Phospholipase A (hnps-PLA).
Synonym:
185298-58-2; 2-(4-(2-Amino-2-oxoethoxy)-1-benzyl-2-ethyl-1H-indol-3-yl)-2-oxoacetamide; 2-{[1-benzyl-3-(carbamoylcarbonyl)-2-ethyl-1H-indol-4-yl]oxy}acetamide; 2-[4-(2-amino-2-oxoethoxy)-1-benzyl-2-ethylindol-3-yl]-2-oxoacetamide
CAS No.:
185298-58-2
Compound CID:
10833571
Formula:
C21H21N3O4
Formula Weight:
379.41
Specification
Relative Density:
1.32 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
hnps-PLA inhibitor can be used in lipid signaling research to study the inhibition of non-pancreatic secretory phospholipase A2.
Library Information
Target:
Phospholipase; LTA4H
Receptor:
hnsPLA2; LTA(4)H-h
Pathways:
Immunology/Inflammation; Metabolism
Plate Number:
AOCL-11
Plate Location:
c3
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
11 mg/mL; 28.99 mM
